After epilepsy setback, Zogenix buys Modis and rare disease drug for $400mZogenix has bounced back from the FDA’s rejection of its only drug, with the acquisition of Modis Therapeutics Share XAfter epilepsy setback, Zogenix buys Modis and rare disease drug for $400mhttps://pharmaphorum.com/news/after-epilepsy-setback-zogenix-buys-modis-and-rare-disease-drug-for-400m/
Rhythm doesn’t miss a beat as obesity drug clears phase 3 testRhythm Pharma says it has reported positive results for its obesity drug setmelanotide in two phase 3 trials, Share XRhythm doesn’t miss a beat as obesity drug clears phase 3 testhttps://pharmaphorum.com/news/rhythm-doesnt-miss-a-beat-as-obesity-drug-clears-phase-3-test/
Daiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumourDaiichi Sankyo’s pexidartinib has become the first FDA-approved therapy for tenosynovial giant cell tumour (TGCT), a rare form Share XDaiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumourhttps://pharmaphorum.com/news/daiichi-sankyos-pexidartinib-is-first-fda-approved-drug-for-rare-tumour/
AI specialist Exscientia forms rare disease JV with RallyBioUK artificial intelligence (AI) drug discovery company Exscientia has formed another R&D alliance, this time in the area Share XAI specialist Exscientia forms rare disease JV with RallyBiohttps://pharmaphorum.com/news/ai-specialist-exscientia-forms-rare-disease-jv-with-rallybio/
Vertex presses go on its cystic fibrosis triple filingVertex has launched the next phase of its plan for the cystic fibrosis market, filing for approval of Share XVertex presses go on its cystic fibrosis triple filinghttps://pharmaphorum.com/news/vertex-presses-go-on-its-cystic-fibrosis-triple-filing/
Celgene gets new approval for soon-to-be-shed OtezlaCelgene has picked up a third approval for its anti-inflammatory drug Otezla, although it won’t reap much commercial Share XCelgene gets new approval for soon-to-be-shed Otezlahttps://pharmaphorum.com/news/celgene-gets-new-approval-for-soon-to-be-shed-otezla/
NICE restores parity between Alnylam and Akcea on rare diseaseNICE has reversed its stance on Alnylam’s gene-silencing drug Onpattro for rare disease hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), Share XNICE restores parity between Alnylam and Akcea on rare diseasehttps://pharmaphorum.com/news/nice-restores-parity-between-alnylam-and-akcea-on-rare-disease/
Alexion’s Soliris follow-up Ultomiris snares EU approvalAlexion has the EU approval it needed for Ultomiris, a follow-up to its rare disease therapy Soliris that Share XAlexion’s Soliris follow-up Ultomiris snares EU approvalhttps://pharmaphorum.com/news/alexions-soliris-follow-up-ultomiris-snares-eu-approval/
Pfizer acquires Therachon and its dwarfism drugPfizer has announced it will pay $340 million upfront to snap up rare disease biotech Therachon, which is Share XPfizer acquires Therachon and its dwarfism drughttps://pharmaphorum.com/news/pfizer-acquires-therachon-and-its-dwarfism-drug/
